US Edition
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
5 Articles
5 Articles
MSD has announced the results of the dose confirmation phase of the phase 2/3 waveLINE-003 study. It evaluates a drug for the treatment of diffuse large B-cell lymphoma (DLBCL) in recurrence or refractory. In addition, the data were first presented during an oral presentation at the 2025 Annual Congress of the American Society of Clinical Oncology (ASCO) In a pre-specified analysis, this drug reached an objective response rate (ORR) of 56.3 perc…
Innate Pharma highlights preclinical antitumor activity of IPH6501 in diffuse large B-cell lymphoma and follicular lymphoma at the 2025 European Hematology Association (EHA) congress
Innate Pharma highlights preclinical antitumor activity of IPH6501 in diffuse large B-cell lymphoma and follicular lymphoma at the 2025 European Hematology Association (EHA) congress Fri, 06/13/2025 - 07:00 Press Release in English 273.45 KB Communiqué de presse en français 179.51 KB mathilde Thu, 06/12/2025
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
To view factuality data please Upgrade to Premium
